Richard Newcomb Stillwell, Director at Tonix Pharmaceuticals Holding Corp. (TNXP), bought 5,000 shares at $11.65 ($58K) on 2026-06-08, disclosed to the SEC on 2026-06-09.
Director Richard Stillwell purchased 5,000 shares of Tonix Pharmaceuticals for $58,250, marking the largest insider purchase in the company's history. This significant buyback at $11.65 comes as the stock trades near its 52-week low, potentially signaling confidence in the company's commercial traction.
TNXP is down 18.13% over the last 90 days and is currently trading 83.64% below its 52-week high of $69.97, while sitting just 5.19% above its 52-week low of $10.88.
1) Q2 2026 earnings on August 10, 2026, with record TONMYA sales of $11 million and prescriptions doubling quarter-over-quarter. 2) A new managed Medicare payer agreement signed on July 13, 2026, extending coverage to 9 million additional beneficiaries. 3) The company is currently in a 'pit cluster' with 1 other insider buying in the last 30 days, indicating a rare reversal of selling pressure.
The stock faces significant volatility with a beta of 1.689 and a short interest of 21.47% of the float, which could amplify price swings. Additionally, the company reported a forward P/E of -1.61, indicating negative earnings expectations.
Nothing distinguishes this filing.